Palatin Technologies (PTN) Closes Mega-Deal with AMAG Pharmaceuticals (AMAG)


Shares of Palatin Technologies, Inc. (NYSEMKT:PTN) climbed more than 10% in pre-market trade Friday as the company said that it received a $60 million initial payment after closing a licensing deal with U.S. drugmaker AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG).

Palatin previously reported that the exclusive licensing agreement – for North American Rights to its candidate Rekyndatm (bremelanotide) for a common female sexual disorder – also calls, among other things, for AMAG Pharmaceuticals to pay the biopharmaceutical company up to $80 million based on the achievement of pre-determined product regulatory milestones and up to $300 million contingent upon meeting certain sales milestones.

PTN stock closed at $0.418, up $0.018 (or +4.50%) with a total volume of 986,010 shares traded on Thursday.

Palatin Technologies, which develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases, has 133.42M shares outstanding, market capitalization (intraday) of $55.77M and PTN stock 52-week range is between $0.36 and $0.90 per share.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at